ACIP releases 2024 recommended immunization schedule for US adults aged 19 or older

The Advisory Committee on Immunization Practices (ACIP) has published its 2024 recommended immunization schedule for adults aged 19 years or older in the United States. This guideline document provides vaccination recommendations but does not represent a clinical study with efficacy or safety outcomes. The publication type is a recommendation schedule, not a research study evaluating intervention effects.

No specific interventions, comparators, or clinical outcomes are reported in this schedule document. The guideline does not include sample size, follow-up duration, or primary or secondary outcomes. Safety information including adverse events, serious adverse events, discontinuations, and tolerability is not reported.

Key limitations include the absence of new efficacy or safety data supporting the recommendations. The schedule represents expert consensus recommendations rather than evidence from a specific clinical trial. Funding sources and potential conflicts of interest are not reported.

For clinical practice, this document provides the official ACIP immunization recommendations for US adults in 2024. Clinicians should reference the complete schedule for specific vaccine indications, timing, and special population considerations. The recommendations should be implemented according to individual patient characteristics and clinical judgment.